![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Active Filter(s):
Details:
BA1105 is a recombinant anti-Claudin18.2 human IgG1 monoclonal antibody for treating Claudin18.2-positive advanced solid tumors. BA1105 alone or in combination with chemotherapeutic agents demonstrated a strong anticancer activity in tumor models.
Lead Product(s): BA1105
Therapeutic Area: Oncology Product Name: BA1105
Highest Development Status: IND Enabling Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2021